32 results
8-K
EX-10.1
nhior
17 Jun 21
PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR the Development of RX-3117
11:35am
8-K
EX-1.1
os891kx41cu1f1 2q1g
6 Oct 20
Processa Pharmaceuticals Announces Pricing of $19.2 Million Public Offering and Uplisting to the Nasdaq Capital Market
4:05pm
424B4
1lkfa b5h21x1tvczrm
5 Oct 20
Prospectus supplement with pricing info
4:16pm